Enovis binding offer for eCential Robotics values French surgical robotics firm at €155 million upfront
A binding offer to acquire eCential Robotics puts Enovis Corporation (NYSE: ENOV) in focus, with an upfront enterprise value set at €155 million and cash consideration of approximately €176 million to be paid to…
Key takeaways
- Enovis Corporation has made a binding offer to acquire French surgical robotics firm eCential Robotics at an upfront enterprise value of €155 million, with cash consideration of about €176 million paid to shareholders at closing.
- Enovis agreed to pay up to €35 million in contingent consideration tied to certain milestones, funded through balance-sheet cash and its existing revolving credit facility with no new equity.
- The acquisition adds robotic automation to Enovis' ASTRA enabling technology platform and is intended to pair with the company's existing ARVIS Augmented Reality System.
- Enovis projects roughly 150 basis points of deal-related adjusted EBITDA margin dilution in 2027, offset by about 50 basis points of underlying improvement for a net 100 basis point headwind, with a return to margin improvement expected in 2028.
- The transaction is expected to close by year-end 2026, subject to regulatory approvals, and cannot be finalized until the French works council information and consultation process concludes.
A binding offer to acquire eCential Robotics puts Enovis Corporation (NYSE: ENOV) in focus, with an upfront enterprise value set at €155 million and cash consideration of approximately €176 million to be paid to eCential shareholders at closing. The deal brings robotic automation capabilities into the ASTRA enabling technology platform. The next confirmable step is a definitive acquisition agreement, pending completion of the information and consultation process with eCential Robotics' works council under French law.
The numbers
Beyond the upfront price, Enovis agreed to pay up to €35 million in contingent consideration tied to the achievement of certain milestones. Funding comes from a combination of cash on the balance sheet and availability under the existing revolving credit facility, with no new equity mentioned.
On margins, Enovis projects roughly 150 basis points of deal-related dilution to adjusted EBITDA margin in 2027. Approximately 50 basis points of underlying improvement are expected to offset part of that drag, leaving a net 100 basis point headwind for the year. Enovis expects to return to year-over-year margin improvement in 2028. Free cash flow conversion is projected to reach 50% in 2027, rising above $100 million, with further improvement guided for 2028 and 2029. These are Enovis' own figures, conditional on the transaction closing.
What the acquisition adds
eCential Robotics was built on more than 15 years of work in computer-assisted surgery and orthopedic robotics, and its modular platform is designed around robotic-assisted surgery workflows. CEO Damien McDonald said the team brings engineering talent and intellectual property, along with a track record of commercializing robotic solutions, and framed the deal as the foundation of Enovis' robotics strategy. The platform is intended to pair with the company's existing ARVIS Augmented Reality System.
eCential Robotics CEO Clément Vidal said the combination allows the company to grow through a shared mission around operating room efficiency. Stéphane Lavallée, founder and chair of eCential Robotics, pointed to Enovis' commitment to advancing the Grenoble operation, which the company positions as a center of excellence for robotics in a region it describes as a medical technology hub.
The transaction is expected to close by year-end 2026, subject to regulatory approvals. The definitive agreement cannot be signed until the French works council consultation concludes. That process is what to watch.